Siddarth Arumugam

Dr. Siddarth Arumugam

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
HHHarshit Harpaldas
Harshit Harpaldas
SASiddarth Arumugam
Siddarth Arumugam
CRChelsey Campillo Rodriguez
Chelsey Campillo Rodriguez
BKBhoomika Ajay Kumar
Bhoomika Ajay Kumar
VSVivian Shi
Vivian Shi
SSSamuel K. Sia
Samuel K. Sia
This article reviews the rapid and unprecedented development, scaleup and deployment of POC devices in response to the COVID-19 pandemic and its implications for the future of diagnostics and digital health.

2 November 2019 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
IBIván C. Balán
Iván C. Balán
JLJavier Lopez-Rios
Javier Lopez-Rios
SNSamiksha Nayak
Samiksha Nayak
CLCody Lentz
Cody Lentz
SASiddarth Arumugam
Siddarth Arumugam
SSSamuel K. Sia
Samuel K. Sia

20 November 2019 in Advanced Materials Technologies
Verified
Journal Article
Closed access
PDF file
SASiddarth Arumugam
Siddarth Arumugam
DCDavid A. M. Colburn
David A. M. Colburn
SSSamuel K. Sia
Samuel K. Sia

1 December 2019 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
SASiddarth Arumugam
Siddarth Arumugam
SNSamiksha Nayak
Samiksha Nayak
TWTaylor Williams
Taylor Williams
FMFrancesco Serra di Santa Maria
Francesco Serra di Santa Maria
MGMariana Guedes
Mariana Guedes
MGMaria Gomes-Solecki
Maria Gomes-Solecki
Single multiplexed assays could replace the standard 2-tiered (STT) algorithm recommended for the laboratory diagnosis of Lyme disease if they perform with a specificity and a sensitivity superior or equal to those of the STT algorithm. We used human serum rigorously characterized to be sera from patients with acute- and convalescent-phase early Lyme disease, Lyme arthritis, and posttreatment Lyme disease syndrome, as well as the necessary controls (n = 241 samples), to select the best of 12 Borrelia burgdorferi proteins to improve our microfluidic assay (mChip-Ld). We then evaluated its serodiagnostic performance in comparison to that of a first-tier enzyme immunoassay and the STT algorithm. We observed that more antigens became positive as Lyme disease progressed from early to late stages. We selected three antigens (3Ag) to include in the mChip-Ld: VlsE and a proprietary synthetic 33-mer peptide (PepVF) to capture sensitivity in all disease stages and OspC for early Lyme disease. With the specificity set at 95%, the sensitivity of the mChip-Ld with 3Ag ranged from 80% (95% confidence interval [CI], 56% to 94%) and 85% (95% CI, 74% to 96%) for two panels of serum from patients with early Lyme disease and was 100% (95% CI, 83% to 100%) for serum from patients with Lyme arthritis; the STT algorithm detected early Lyme disease in the same two panels of serum from patients with early Lyme disease with a sensitivity of 48.5% and 75% and Lyme arthritis in serum from patients with Lyme arthritis with a sensitivity of 100%, and the specificity was 97.5% to 100%. The mChip-Ld platform outperformed the STT algorithm according to sensitivity. These results open the door for the development of a single, rapid, multiplexed diagnostic test for point-of-care use that can be designed to identify the Lyme disease stage.

6 June 2019 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
SNSamiksha Nayak
Samiksha Nayak
TGTiffany Guo
Tiffany Guo
JLJavier Lopez-Rios
Javier Lopez-Rios
CLCody Lentz
Cody Lentz
SASiddarth Arumugam
Siddarth Arumugam
SSSamuel K. Sia
Samuel K. Sia
With point-of-care (POC) diagnostic devices becoming increasingly available to untrained users, it will be critical to understand how real-world user behavior can best inform and guide the engineering design process. Social sciences present frameworks for analyzing user behavior, but they have not yet been applied to POC diagnostics in a methodical manner. Here, we develop a framework that synthesizes two models that can collectively account for user behavior and experience with POC diagnostic devices: a social psychological information-motivation-behavior (IMB) model (first described by Fisher and Fisher) for identifying determinants for health-related behavior, and user experience (UX) elements for studying interactions between users and products. Based on studies of 40 naïve users of our smartphone-enabled microfluidics device that can be used for HIV home-testing, we found that untrained participants could perform 90% of steps correctly, with engineering design elements that provided feedback that was either direct (e.g., a light or click) or binary (e.g., a switch) enhancing usability. Interestingly, of the steps performed incorrectly, over 70% were due not to errors in the device or user operation, but user-to-user variability (e.g. time in collecting fingerstick and force applied to initiate vacuum), which could be addressed by further modifications to the device. Overall, this study suggests that microfluidic POC HIV home-testing is likely to benefit from smartphone integration, and that engineering design of POC diagnostic devices can benefit from a structured evaluation of user behavior and experience, as guided by a social-psychological framework, which emphasizes user credibility, accessibility, acceptability, usability, and value.

1 November 2020 in Kidney International Reports
Verified
Journal Article
Open access
JSJacob S. Stevens
Jacob S. Stevens
KXKatherine Xu
Katherine Xu
ACAlexa Corker
Alexa Corker
TGTejashree S. Gopal
Tejashree S. Gopal
OSOsman R. Sayan
Osman R. Sayan
JBJonathan Barasch
Jonathan Barasch
The identification of acute injury of the kidney relies on serum creatinine (SCr), a functional marker with poor temporal resolution as well as limited sensitivity and specificity for cellular injury. In contrast, urinary biomarkers of kidney injury have the potential to detect cellular stress and damage in real time. To detect the response of the kidney to injury, we have tested a lateral flow dipstick that measures a urinary protein called neutrophil gelatinase-associated lipocalin (NGAL). Analysis of urine was performed in a prospective cohort of 479 patients (final cohort N = 426) entering an emergency department in New York City and subsequently admitted for inpatient care. Colorimetric development had high interrater reliability (88% concordance rate) and correlated with traditional enzyme-linked immunosorbent assay (ELISA) measurements (ρ = 0.732, P < .0001). Of the 14% of the cohort who met Acute Kidney Injury Network (AKIN) SCr criteria for acute kidney injury (AKI), 67% demonstrated transient (2 days) elevation of SCr. Comparing the outcomes of patients with sustained versus transient or undetectable changes in SCr revealed that the urinary NGAL (uNGAL) dipstick had high specificity and negative predictive value (NPV) (high- vs. low-intermediate readings, sensitivity = 0.55, specificity = 0.91, positive predictive value = 0.24, NPV = 0.97, χ2 = 20.39, P < 0.001). We show that the introduction of a bedside uNGAL dipstick permits accurate triage by identifying individuals who do not have tubular injury. In an era of shortening length of stay and rapid decisions based on isolated SCr measurements, real-time exclusion of kidney injury by a dipstick will be particularly useful to overcome the retrospective, insensitive, and nonspecific attributes of SCr.